Abstract Plasma phosphorylated-tau181 (p-tau181) showed the potential for Alzheimer's
diagnosis and prognosis, but its role in detecting cerebral pathologies is unclear. We aimed …

Introduction We examined and compared plasma phospho-tau181 (pTau181) and total
tau:(1) across the Alzheimer's disease (AD) clinical spectrum;(2) in relation to brain amyloid …

Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …

To assess plasma phosphorylated tau181 (p-tau181) as a progression biomarker in
Alzheimer's disease (AD), we examined longitudinal plasma p-tau181 of 1184 participants …

Background There is still a substantial unmet need for less invasive and lower-cost blood-
based biomarkers to detect brain Alzheimer's disease (AD) pathology. This study is aimed to …

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …

Background: Plasma phosphorylated-tau181 (p-tau181) is a promising biomarker for
Alzheimer's disease (AD) and may offer utility for predicting preclinical disease. Objective …

Background: Plasma-based biomarkers would be potential biomarkers for early diagnosis of
Alzheimer's disease (AD) because they are more available and cost-effective than …

Background Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for
Alzheimer's disease (AD). Studies have reported strong associations between p-tau and tau …

Abstract Objective Plasma phosphorylated‐tau‐181 (p‐tau181) reliably detects clinical
Alzheimer's disease (AD) as well as asymptomatic amyloid‐β (Aβ) pathology, but is …